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ABSTRACT
The purpose of this study was to reveal treatment outcomes and toxicity after pelvic intensity-modulated radiotherapy
(IMRT) for postoperative uterine cervical cancer of Japanese patients. Consecutive patients who were treated with
pelvic IMRT for postoperative cervical cancer in our institute were retrospectively analyzed. Relapse-free survival
(RFS) and overall survival (OS) were calculated using the Kaplan–Meier estimator, and log-rank tests were used to
compare differences. From the database, 62 patients were identified. The pathology was squamous cell carcinoma in
44 patients and other pathology in 18 patients. Of the 62 patients, 35 had high-risk prognostic factors and 27 patients
had intermediate-risk prognostic factors. The prescribed radiation doses were 50 Gy in 25 fractions for 58 patients and
50.4 Gy in 28 fractions for 4 patients. One patient received a vaginal cuff boost. Chemotherapy was administered in
36 patients. During the median follow-up period of 50.9 months, there was no locoregional failure. Six patients in the
high-risk group relapsed, but none of the patients in the intermediate-risk group relapsed (P = 0.02). The 3-year OS
and RFS rates were 98.2% and 90.9%, respectively. Significant factors related to RFS were squamous cell carcinoma
pathology (P = 0.02), pathological T stage (P = 0.04), surgical margin status (P < 0.01) and multiple lymph nodes
metastases (P < 0.01). Grade 3 or more toxicity occurred in 6 patients. Four patients had obstruction of the intestine,
and 2 patients had stenosis of the urinary tract. In clinical practice, the use of pelvic IMRT for postoperative cervical
cancer of Japanese patients showed a low rate of toxicity without decreasing the efficacy.
Keywords: postoperative; pelvic radiotherapy; uterine cervical cancer; intensity-modulated radiotherapy; VMAT;
IMRT
INTRODUCTION
Definitive treatment for early-stage uterine cervical cancer is surgery
or radiotherapy with or without chemotherapy. In surgical treatments,
adjuvant treatment for patients who have prognostic risk factors after
radical hysterectomy has been recommended [1, 2]. Adjuvant treat-
ment is also recommended in Japanese treatment guidelines for uterine
cervical cancer, but adjuvant treatment has not always been used in
clinical practice in Japan. A clinical survey conducted in 2010 and 2014
in Japan showed that >80% of institutions in Japan chose surgery as
the primary therapy for Stage IB1 and IIA1 tumors, and chemotherapy
alone as an adjuvant treatment was considered one of the key options
in 72% of institutions in expectation of the reduction of complications
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caused by radiotherapy [3–5]. Since then, prospective trials have fol-
lowed the clinical practice [6]. However, radiotherapy now has reduced
complications through the use of the intensity-modulated radiation
therapy (IMRT) technique [7, 8]. It has been reported that IMRT dra-
matically reduced the incidence of complications compared with the
level when 3D radiotherapy (3DRT) was used in postoperative uterine
cancer patients. IMRT decreased the 3-year cumulative incidence of
Grade 2 or higher gastrointestinal toxicity from 45% to 3% [9]. It has
also been reported that IMRT might contribute more than 3DRT to a
better quality of life. [10].
In spite of these progressions, gynecological oncologists in Japan
tend to shun radiotherapy. However, pelvic IMRT has been positively
used in a postoperative setting in our institute in collaboration with
gynecological oncologists. The aim of this study was to reveal the treat-
ment outcomes and toxicities after pelvic radiotherapy for postopera-
tive cervical cancer in clinical practice in an academic environment. It
was predicted that the results would provide important data, especially
for the benefit of Japanese patients.
MATERIALS AND METHODS
Eligibility and informed consent
Patients who received pelvic radiotherapy or chemoradiotherapy
involving IMRT for postoperative uterine cervical cancer in our
hospital were included in this study. Patients who had been treated with
only cervical conization, or patients who had already relapsed before
radiotherapy, were not considered to be in a postoperative condition.
To avoid selection bias, all of the remaining patients, i.e. consecutive
patients who received pelvic IMRT for postoperative cervical cancer,
were enrolled in this retrospective study. This study was approved by
the Ethical Committee of Tohoku University Hospital (No. 2019–1-
648). Informed consent was waived due to the retrospective nature of
this study. All patients were guaranteed the chance to restrict their data
use in this study by giving information on this study via the Internet.
Furthermore, written informed consent as a part of general consent
for utilization of treatment data in future retrospective studies was
obtained from all patients who have been treated after April 2016.
CT simulation and radiotherapy
Before CT simulation, two small cotton balls were inserted into the
vaginal cuff of each patient. Each patient was immobilized in the supine
position with a vacuum cushion (VacQfix Cushion, Qfix, Avondale PA,
USA). Treatment planning CT scans at intervals of 2.0–2.5 mm were
performed in a full bladder state, and CT scans in a empty bladder were
also performed to compensate for internal organ motion. The nodal
clinical target volume (CTV) was contoured on the basis of the Japan
Clinical Oncology Group ( JCOG) consensus-based guideline [11].
The vaginal and parametrial CTV was contoured 1.0–1.5 cm superiorly
from the inserted cotton and 3–4 cm inferiorly or at the bottom level
of the obturator foramen. The vaginal and parametrial internal target
volume (ITV) was created from the vaginal and parametrial CTV
and empty bladder CT scans. The planning target volume (PTV) was
created by expanding 0.7 cm from the nodal CTV and 1.0 cm from the
vaginal CTV in all directions. In principal, 50 Gy in 25 fractions cover-
ing 90% of the PTV were prescribed, and radiotherapy was performed
under the image guidance using a linear accelerator equipped with
cone-beam CT. IMRT was performed using the volumetric-modulated
arc therapy (VMAT) technique, and coplanar multi-arc beams with
10 MV or 15 MV photons were used. Dose distribution in the PTV
also needed the maximum dose to be < 115% of the prescribed dose,
< 1% of the PTV to receive >110% of the prescribed dose, and >99%
of the PTV to receive >91% of the prescribed dose. An organ at
risk was contoured on the basis of the ‘Female RTOG Normal Pelvis
Atlas’ provided by the Radiation Therapy Oncology Group (RTOG).
Normal tissue dose constraints were as follows: < 35% of the bladder
received <45 Gy; <80% and <35% of the rectum received <40 Gy
and <50 Gy, respectively; <30% and maximum dose of the bowel
bag received <40 Gy and <110% of the prescribed dose, respectively;
<37% and <90% of the pelvic bone received <40 Gy and <10 Gy,
respectively; and <40% of the femoral heads received <30 Gy. When
there were transposed ovaries, the mean dose each ovary received was
<3 Gy or <7 Gy, which were the desired value and tolerant value,
respectively. A vaginal cuff boost using intracavitary brachytherapy was
performed when there was a residue of invasive cancer: typically, 12 Gy
in 2 fractions prescribed at 5 mm beyond the vaginal mucosa.
Postoperative risk factors and chemotherapy
Patients in the high-risk prognostic factor group were defined as
patients with at least one of the high-risk prognostic factors, including
positive pelvic lymph nodes, parametrial extension, and positive surgi-
cal margins [12]. An additional risk factor was metastasis to the ovary.
Patients in the intermediate-risk prognostic factor group were defined
as patients with at least one of the intermediate-risk prognostic factors
without high-risk prognostic factors. The intermediate-risk prognostic
factors were: greater than one-second stromal invasion, lymphovascu-
lar space invasion, and cervical tumor diameters of >4 cm.
Chemotherapy was performed in patients with high-risk prognostic
factors. On the other hand, patients in the intermediate-risk group were
treated with radiotherapy alone. When the pathology was squamous
cell carcinoma, adenocarcinoma, or adenosquamous carcinoma,
concurrent chemotherapy was platinum monochemotherapy. In our
hospital, weekly cisplatin (40 mg/m2) was administered for up to
five cycles, and if the patients was intolerant to cisplatin, weekly
nedaplatin was used as an alternative [13]. Adjuvant chemotherapy
was not administered. When the pathology was neuroendocrine
tumors (typically small-cell carcinoma or large-cell neuroendocrine
carcinoma), concurrent and adjuvant chemotherapy was performed,
with three cycles of a regimen consisting of vincristine, adriamycin and
cyclophosphamide alternating with cisplatin and etoposide (VAC/PE)
[14].
Outcome and toxicity assessment
Locoregional relapse was defined as any intrapelvic recurrence
or metastasis excluding pelvic bone metastasis and peritoneal
dissemination, and locoregional control was defined as freedom
from locoregional relapse. Relapse-free survival (RFS) was defined
as freedom from any metastases, any recurrences, dissemination or
death. Overall survival (OS) was defined as freedom from death by all
causes. Toxicity was assessed from the day radiotherapy was started.
Acute toxicity of (chemo)radiation was assessed according to the
National Cancer Institute Common Terminology Criteria for Adverse
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Table 1. Patient demographics at the time of radiotherapy
Characteristics Number (%)
Patients 62
Age, years Median, range 45, 29–79
Period of surgery September 2013 – February 2019
Surgery type Radical hysterectomy 58 (93.5)
Total hysterectomy 4 (6.4)
Pathology Squamous cell carcinoma 44 (70.9)
Adenocarcinoma 11 (17.7)
Mixed 1 (1.6)
Adenosquamous carcinoma 3 (4.8)
Neuroendocrine carcinoma 3 (4.8)










Parametrial extension Yes 15 (24.1)
No 47 (75.8)
Nodal involvement None 34 (54.8)
1 7 (11.2)
≥2 21 (33.8)
Surgical margin (microscopic positive margin) Yes 2 (3.2)
No 60 (96.7)
Stromal invasion ≥1/2 45 (72.5)
<1/2 17 (27.4)
Lymphovascular space invasion Yes 34 (54.8)
No 28 (45.1)
Tumor diameter, cm Median, range 3.0, 0.5–7.4
Prognostic risk group High-risk group 35 (56.4)
Intermediate-risk group 27 (43.5)
Ovarian transposition Yes 19 (30.6)
No 43 (69.3)
Interval between surgery and radiotherapy, days Median, range 51 (27–109)
Events version 5.0 translated by the Japanese Clinical Oncology Group
(CTCAE v5.0-JCOG). Late toxicity was graded according to the
RTOG Late Radiation Morbidity Scoring Scheme [15]. Urinary tract
obstruction and lymph edema were assessed using CTCAE v5.0-JCOG
because there was no adequate definition in the RTOG scheme.
Statistical analysis
The time to an event was calculated from the day of definitive surgery
to the day that an event was confirmed. The cumulative RFS rate and
the OS rate were calculated using the Kaplan–Meier estimator, and
the log-rank test was used to compare differences. A P value less than
0.05 was defined as significant. EZR version 1.37 (Saitama Medical
Center, Jichi Medical University, Saitama, Japan), a modified version
of R commander (R Foundation for Statistical Computing, Vienna,
Austria), was used for analyses [16].
RESULTS
Patients
A total of 62 patients were identified from our database. Patient demo-
graphics at the time of radiotherapy are summarized in Table 1. Of
the 62 patients, 58 received radical hysterectomy and 4 received total
hysterectomy; 19 patients aged from 29 to 43 years received ovarian
transposition. There was no macroscopic residual case, and only two
cases showed a microscopic positive surgical margin, including one
case of carcinoma in situ. Of the 62 patients, 35 had high-risk prognostic
factors and 27 had only intermediate-risk factors.
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Table 2. Chemoradiotherapy characteristics and patterns of recurrence
Characteristics Number (%)
Radiotherapy 50 Gy/25fr 58 (93.5)
50.4 Gy/28fr 4 (6.4)
Intracavitary brachytherapy boost 12 Gy/2fr 1 (1.6)








Patterns of recurrence Lung 2
Liver 1
Lymph nodes 1
Lymph nodes and bone 1
Peritoneal dissemination and spleen 1
The results of radiotherapy and chemoradiotherapy are summa-
rized in Table 2. The prescribed radiation doses were 50 Gy in 25 frac-
tions in 58 patients, or 50.4 Gy in 28 fractions in 4 patients. One patient
who had a positive surgical margin received a vaginal cuff boost, using
intracavitary brachytherapy with 12 Gy in 2 fractions. Chemotherapy
was administered in 36 patients, including 2 of the 4 patients who
received only total hysterectomy in the intermediate-risk group. One
patient in the high-risk group who had one high-risk factor (a positive
surgical margin) did not receive chemotherapy. All patients completed
the planned radiotherapy.
Treatment outcomes
The median follow-up period was 50.9 months (range, 14.6–
133.7 months), and one patient died of primary disease. There was
no case of locoregional relapse. Six patients relapsed, and all of
those patients were in the high-risk group. Initially relapsed sites are
summarized in Table 2. Two cases developed lymph nodes recurrence,
and both cases developed simultaneously para-aortic lymph nodes and
supraclavicular lymph nodes recurrence. The 3-year OS and RFS rates
were 98.2% [95% confidence interval (95% CI): 87.8–99.7%] and
90.9% (95% CI: 79.5–96.1%), respectively (Fig. 1). The 3-year RFS
rates in the intermediate-risk and high-risk groups were 100.0% (95%
CI: 100.0–100.0%) and 84.3% (95% CI: 66.2–93.2%), respectively,
and the difference was significant (P = 0.02, Fig. 2). Variables of clinical
and pathological findings were also compared using log-rank tests
(Table 3). As a result, variables that were significant factors for RFS
were pathology (squamous cell carcinoma vs others, P = 0.02), pT1 vs
pT2 (P = 0.04), surgical margin status (P < 0.01) and pathological
multiple lymph nodes metastases (P < 0.01). Ovarian function
was maintained in 8 of 19 patients (5 of 11 patients who received
chemoradiotherapy and 3 of 8 patients who received radiotherapy
alone) who received ovarian transposition with a mean irradiated
ovarian dose of 4.3 ± 2.0 Gy.
Toxicities
Dose calculation results of parameters for an organ at risk are shown
in Table 4, and acute and late toxicities are summarized in Table 5.
Grade 3 or more late toxicities occurred in 6 patients. Four patients had
obstruction of the intestine, and perforation of the intestine occurred in
one of those patients. The other two patients had urinary tract stenosis,
which developed into severe hydronephrosis. Repeated admission to
the hospital because of obstruction of the intestine was needed in four
patients: three times in one patient, five times in one patient and six
times in two patients. The 3-year cumulative incidence of Grade 3 or
higher gastrointestinal toxicity was 5.8% (95% CI: 0.0–12.0%, Fig. 3).
DISCUSSION
Although this study was a retrospective study conducted in a single
institute in an academic environment, the results were meaningful,
especially for Japanese patients. They accurately reflected outcomes
in clinical practice owing to the inclusion of all patients who received
pelvic IMRT for postoperative uterine cervical cancer in our institute.
Pelvic IMRT for postoperative cervical cancer showed a low rate of tox-
icity without decreasing the efficacy; on the contrary, the result showed
perfect locoregional control, and the locoregional control clearly con-
tributed to excellent RFS. Pelvic IMRT might not only enable reduc-
tion of complications but also improve treatment outcomes compared
with those in previous studies [5, 12, 17]. There are several possible
reasons for the different results. First, the vaginal cuff was carefully tar-
geted using cotton balls and cautiously irradiated by using cone-beam
CT image guidance. Furthermore, cone-beam CT provided informa-
tion about changes of ascites and body contour for considering replan-
ning. Third, the JCOG consensus-based guideline for nodal CTV was
described in detail; therefore, the nodal target was created larger than
that based on the RTOG guideline [11]. Finally, the doses prescribed
covered 90% of the PTV, greatly reducing the possibility of an under-
dose area within the PTV.
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Fig. 1. Kaplan–Meier curves of locoregional control (LRC), overall survival (OS) and relapse-free survival (RFS).
Fig. 2. Kaplan–Meier curves of relapse-free survival (RFS) according to prognostic risk factors. The 3-year RFS rates in the
intermediate-risk and high-risk groups were 100.0% and 84.3%, respectively. The difference showed significance (P = 0.02,
log-rank test).
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Table 3. Results of log-rank tests for RFS
Variables No. 3-year RFS P value
Age, years
≤45 30 91.8
>45 32 90.2 0.49
Surgery type
Radical hysterectomy 58 90.4
Total hysterectomy 4 100.0 0.53
Pathology
Squamous cell carcinoma 44 95.1
Others 18 80.8 0.02
Pathological T stage
pT1 42 97.1
pT2 20 78.5 0.04
Parametrial extension
Yes 15 78.8
No 47 95.0 0.12
Tumor diameter, cm
≤4 50 88.6
>4 12 100.0 0.20
Surgical margin (microscopic positive)
Yes 2 Not reached
No 60 92.4 <0.01
Pathological N stage
pN0 34 96.2
pN1 28 85.4 0.05
Nodal involvement
0–1 41 97.0
≥2 21 80.4 <0.01
Lymphovascular space invasion
Yes 34 90.6
No 28 91.3 0.55
Stromal invasion
<1/2 17 93.8
≥1/2 45 89.9 0.53
RFS = relapse-free survival, No. = number of patients.
Table 4. Dose calculation results of parameters for organ at risk
Structure Median Interquartile range Range
Bladder
Percentage of patients who received 45 Gy or more 42.0 34.2–52.8 24.7–81.9
Bowel bag
Maximum dose (Gy) 54.4 54.0–54.7 52.6–55.1
Percentage of patients who received 40 Gy or more 28.7 25.3–31.9 12.6–54.7
Rectum
Percentage of patients who received 40 Gy or more 65.8 58.3–73.7 36.8–97.3
Pelvic bone
Percentage of patients who received 40 Gy or more 27.8 24.1–31.0 15.2–42.0
Percentage of patients who received 10 Gy or more 95.1 90.0–99.0 81.7–100.0
Ovaries (19 patients)
Mean ovarian dose (Gy) 4.8 1.9–5.9 1.0–7.5
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Table 5. Toxicities
Type of toxicity Grade 2 or more Grade 3 or more
Acute toxicities of chemoradiation
Gastrointestinal 21 (69.0) 7 (11.2)
Hematologic 31 (86.1) 20 (55.5)




Bowel obstruction 8 (12.9) 4 (6.4)
Urinary tract 2 (3.2)
Lymph edema 3 (4.6)
There was no Grade 2 or more toxicity regarding bowel bleeding and bladder. Data are expressed as number (%).
Fig. 3. Cumulative incidence of Grade 3 or higher gastrointestinal toxicity starting from the first day of radiotherapy. The 3-year
cumulative incidence was 5.8% (95% CI: 0.0–12.0%).
Although there were good results for RFS in this study, the pos-
sible prognostic factors for RFS were almost the same as those pre-
viously reported [18]. Pelvic lymph node involvement was regarded
as a high-risk factor, but the number of positive lymph nodes might
also be important [5, 12, 19, 20]. Patients with squamous cell car-
cinoma also showed better RFS in several studies [5, 21, 22]. The
emergence of these factors, despite sophisticated radiation techniques,
might suggest the need for reinforcement of concurrent or adjuvant
chemotherapy.
Ovarian function was maintained in only 8 of the 19 patients, and
this result is not satisfactory [23]. Suppression of ovarian function is
caused by chemotherapy and radiotherapy, especially by exposure of
the ovaries to high radiation doses. The ovary is very radiosensitive,
and strict restriction of the mean ovarian dose to 2.5–3.4 Gy in one
study resulted in the maintenance of ovarian function in 5 (71%) of 7
patients [24]. Transposition of the ovaries out of the irradiation field
is important for reducing ovarian doses. Four patients in that study
had ovarian transposition at 3–3.5 cm above the level of L5–S1, and 1
patient had ovarian transposition at 1.5 cm from the radiation field edge
[24]. In the present study, the mean ovarian doses were 1.5 ± 0.54 Gy
when the ovaries were located above the PTV and 5.3 ± 0.32 Gy when
the ovaries were located at the same level as the PTV (data not shown
in the Results section). When the ovaries are located above the PTV,
the ovaries are affected only by secondary radiation doses from IMRT
and cone-beam CT with or without chemotherapy. On the other hand,
when the ovaries are located at the same level as the PTV, the ovaries are
affected by not only scattering but also by direct radiation of cone-beam
CT, IMRT and leakage doses from the multileaf collimator. In such
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cases, the usual IMRT (VMAT) technique of strict dose constraints
and the set of beam avoidance sector where the beam was turned off
during VMAT were unsatisfactory, and the use of a special technique
such as the restricted field technique might therefore be desirable [25].
The incidence of bowel obstruction was comparable with or lower
than that in previous studies [5, 26]. According to a nationwide cohort
study in Japan, Grade 3–4 bowel obstruction was observed in 7.4% of
patients who received postoperative pelvic radiotherapy alone, 9.7%
of patients who received postoperative pelvic chemoradiotherapy and
3.2% of patients who received adjuvant chemotherapy alone [27]. In
this study, Grade 3–4 bowel obstruction occurred in 4 (6.4%) of the
patients, and those 4 patients required repeated admission because of
bowel obstruction. The rate of bowel obstruction was relatively low,
but might not be considered satisfactory, compared with the rate after
adjuvant chemotherapy alone. These are reasons why many gyneco-
logical oncologists shun radiotherapy. Since internal motion of the
postoperative bowel is thought to be restricted because of postopera-
tive adhesion, the definition of the bowel bag, dose constraints for the
bowel and dose prescription should be reconsidered.
There are several limitations in the current study. This study was a
retrospective single-institute study with a limited sample size. Because
only six patients relapsed, multivariate analysis was not performed.
Some heterogeneity of treatment (either surgery or radiotherapy) was
seen. The indication for radiotherapy in patients with intermediate-risk
factors, and the definition of intermediate-risk factors, especially the
extent of stromal invasion, were controversial.
In conclusion, pelvic IMRT for postoperative cervical cancer of
Japanese patients showed a low rate of late toxicities, without decreas-
ing the efficacy, and these results were comparable with previous find-
ings.
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